Date: 2011-08-23
Type of information:
phase: 3
Announcement: authorization
Company: PharmaNeuroBoost (Belgium)
Product: PNB01
Action mechanism: combination of citalopram and a low dose of pipamperone
Disease: major depression disorder (MDD)
Therapeutic area: Mental diseases - CNS diseases
Country: USA
Trial details:
Latest news: Pharmaneuroboost has received clearance from the Institutional Review Board (IRB) to initiate its first phase III study with PNB01 in the USA. PNB01 is the first of two front-running, late stage proprietary projects of PNB.
